ACETAZOLAMIDE MARKET ANALYSIS

Market Challenges And Opportunities

Furthermore, along with chronic simple (open-angle) glaucoma, secondary glaucoma and acute mountain sickness in climbers; acetazolamide is also indicated for adjective treatment of edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies.

Increasing prevalence of glaucoma and associated risk factors such as high myopia, diabetes, eye surgery or injury, high blood pressure, increased usage of corticosteroids, and family history of glaucoma among the global population are expected to offer conducive future growth for acetazolamide drug manufacturers. As a sustained release capsule of Acetazolamide taken a day, offers a substantial pressure-lowering effect that lasts at least 23 hours. Treatment with acetazolamide helps to reduce eye pressure, which aids in preventing eye damage. Acetazolamide works by blocking the action of an enzyme called carbonic anhydrase thereby, reducing the amount of fluid secreted in the front part of eye, thus lowering eye pressure. For instance, according to the study published in the Journal of Ophthalmology (2014), an estimated 64.3 million people (aged 40-80 years) in 2013, were affected with glaucoma, which would increase to 76.0 million in 2020, and 111.8 million in 2040.

According to the International Agency for the Prevention of Blindness, 2017, glaucoma is the second leading cause of blindness and leading cause of irreversible blindness worldwide. With primary angle closure glaucoma (PACG) being the most common in South-East Asia  while primary open-angle glaucoma (POAG) is mostly found among white Caucasians and individuals of Africa.